Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 12, 2019 and accepted by EDGAR at Nov 12, 2019, 09:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-07-01 to 2019-09-30$546.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2019-01-01 to 2019-09-30$2.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2019-07-01 to 2019-09-30$11.1mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-01-01 to 2019-09-30$32.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2019-07-01 to 2019-09-30−$11.8mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30−$42.0mus-gaap:OperatingIncomeLoss
Net income3 months2019-07-01 to 2019-09-30−$11.4mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income9 months2019-01-01 to 2019-09-30−$40.4mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2019-07-01 to 2019-09-30−$0.75us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30−$2.92us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2019-01-01 to 2019-09-30−$35.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2019-01-01 to 2019-09-30$626.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-09-30$16.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$75.1mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$131.8mus-gaap:Assets
Current liabilitiesAt period end2019-09-30$11.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$30.5mus-gaap:Liabilities
Shareholders' equityAt period end2019-09-30$101.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-19-062181. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.